Rating Change
UBS analysts reiterated a Neutral rating on Exelixis, Inc. (NASDAQ:EXEL) on July 02, 2026.
reiterateNASDAQ:EXEL
UBS Reiterates Neutral Rating on Exelixis, Inc. (EXEL)
Rating Change UBS analysts reiterated a Neutral rating on Exelixis, Inc. (NASDAQ:EXEL) on July 02, 2026. Market Context Exelixis, Inc.
Market Context
Exelixis, Inc. operates in the Healthcare sector. The stock currently trades at $54.90 with a market capitalization of $11.1B. The stock has gained 22.4% over the past 52 weeks.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Exelixis, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Exelixis, Inc.
Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 02, 2026 | UBS | Neutral | N/A |
| Jul 02, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 25, 2026 | Truist Securities | Hold | N/A |
| Jun 24, 2026 | Citizens | Market Outperform | N/A |
| May 07, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View EXEL Stock Page
Frequently Asked Questions
What does a Neutral rating mean for EXEL?
A Neutral rating from UBS reflects the analyst's outlook on Exelixis, Inc. (NASDAQ:EXEL). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the EXEL forecast page.